

DEA Poised to Renew Extension of Telehealth Flexibilities for Prescribing Controlled Substances

[Digital Health](#)

11.18.25

The Drug Enforcement Administration (DEA) appears to be preparing to extend, for the fourth time, the telehealth flexibilities that allow clinicians to prescribe controlled substances without an initial in-person visit—a policy originally introduced during the COVID-19 public health emergency. According to a [notice](#) currently under review at the Office of Management and Budget (OMB), the rule titled “*Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications*” signals that these provisions will remain in place beyond their current expiration date of December 31, 2025.

RELATED CAPABILITIES

[Digital Health](#)